Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Astrid Jullion"'
Autor:
Mélanie Wilbaux, David Demanse, Yi Gu, Astrid Jullion, Andrea Myers, Vasiliki Katsanou, Christophe Meille
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 1122-1134 (2022)
Abstract Machine learning (ML) opens new perspectives in identifying predictive factors of efficacy among a large number of patients’ characteristics in oncology studies. The objective of this work was to combine ML with population pharmacokinetic/
Externí odkaz:
https://doaj.org/article/210944c07ba5437595e64f107a7269f0
Autor:
Oliver Sander, Baldur Magnusson, Inga Ludwig, Astrid Jullion, Christophe Meille, Daniel Lorand, Björn Bornkamp, Markus Hinder, Steven J. Kovacs, Michael Looby
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1276-1280 (2021)
Abstract Optimizing new drug therapies remains a challenge for clinical development, despite the use of ever more sophisticated quantitative methodologies. Although conceptually simple, the idea of finding the right treatment at the right dose for th
Externí odkaz:
https://doaj.org/article/15d1549b9b844cf58ce62297612b8cf4
Autor:
Mélanie Wilbaux, Shu Yang, Astrid Jullion, David Demanse, Diana Graus Porta, Andrea Myers, Christophe Meille, Yi Gu
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:1329-1339
Model-informed dose selection has been drawing increasing interest in oncology early clinical development. The current paper describes the example of FGF401, a selective fibroblast growth factor receptor 4 (FGFR4) inhibitor, in which a comprehensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa51648b7bb57396c59e89a3f541768b
https://doi.org/10.1002/cpt.2752
https://doi.org/10.1002/cpt.2752
Autor:
William R. Sellers, Francesco Hofmann, Michael R. Jensen, Marion Wiesmann, Emil Kuriakose, Audrey Kauffmann, Astrid Jullion, Ensar Halilovic, Nelson Guerreiro, Jens Würthner, Pascal Furet, Joerg Kallen, Therese-Marie Stachyra, Stephan Ruetz, Marta Cortes-Cros, Swann Gaulis, Eric Y. Durand, Grainne Kerr, Masato Murakami, Vincent Romanet, Dario Sterker, Markus Wartmann, Emilie A. Chapeau, Jeanette Fuchs, Philipp Holzer, Stéphane Ferretti, Sébastien Jeay
Median of the shRNAs and RSA values. File containing median counts and log fold changes of each gene from Supplementary Data File S1. According significance values of each gene as activator or sensitizer compared to DMSO control (see Methods) are inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9fb2879a6749b92d41888b92af04a38
https://doi.org/10.1158/0008-5472.22420067.v1
https://doi.org/10.1158/0008-5472.22420067.v1
Autor:
Antoine Italiano, Jean-Yves Blay, Claire Fabre, Ensar Halilovic, Janna Sand Dejmek, Giorgia Clementi, Elena J. Orlando, Astrid Jullion, Nelson Guerreiro, Stephane Ferretti, Ricardo Cubedo, Marie Luise Hütter-Krönke, Richard Quek, Chia-Chi Lin, Cristina Suarez, Sebastian Bauer, Albiruni R. Abdul Razak
Purpose:Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent kinase-4 (CDK4) oncogenes. Siremadlin, a p53–MDM2 inhibitor, was combined w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a971100db2252b3b049d87afe798e6c
https://doi.org/10.1158/1078-0432.c.6530853
https://doi.org/10.1158/1078-0432.c.6530853
Autor:
Antoine Italiano, Jean-Yves Blay, Claire Fabre, Ensar Halilovic, Janna Sand Dejmek, Giorgia Clementi, Elena J. Orlando, Astrid Jullion, Nelson Guerreiro, Stephane Ferretti, Ricardo Cubedo, Marie Luise Hütter-Krönke, Richard Quek, Chia-Chi Lin, Cristina Suarez, Sebastian Bauer, Albiruni R. Abdul Razak
Supplementary Data from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4dd91876970741eba8a728113773c0c
https://doi.org/10.1158/1078-0432.22482189
https://doi.org/10.1158/1078-0432.22482189
Autor:
Antoine Italiano, Jean-Yves Blay, Claire Fabre, Ensar Halilovic, Janna Sand Dejmek, Giorgia Clementi, Elena J. Orlando, Astrid Jullion, Nelson Guerreiro, Stephane Ferretti, Ricardo Cubedo, Marie Luise Hütter-Krönke, Richard Quek, Chia-Chi Lin, Cristina Suarez, Sebastian Bauer, Albiruni R. Abdul Razak
Supplementary Figure from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ae5a9dcf4c27f6f610b888e4fe9a1a
https://doi.org/10.1158/1078-0432.22482183.v1
https://doi.org/10.1158/1078-0432.22482183.v1
Autor:
William R. Sellers, Francesco Hofmann, Michael R. Jensen, Marion Wiesmann, Emil Kuriakose, Audrey Kauffmann, Astrid Jullion, Ensar Halilovic, Nelson Guerreiro, Jens Würthner, Pascal Furet, Joerg Kallen, Therese-Marie Stachyra, Stephan Ruetz, Marta Cortes-Cros, Swann Gaulis, Eric Y. Durand, Grainne Kerr, Masato Murakami, Vincent Romanet, Dario Sterker, Markus Wartmann, Emilie A. Chapeau, Jeanette Fuchs, Philipp Holzer, Stéphane Ferretti, Sébastien Jeay
Activation of p53 by inhibitors of the p53–MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, and selective inhibitor of the p53–MDM2 interaction H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::defcbf6d8ab85cdf500b16956270b3ec
https://doi.org/10.1158/0008-5472.c.6510551.v1
https://doi.org/10.1158/0008-5472.c.6510551.v1
Autor:
William R. Sellers, Francesco Hofmann, Michael R. Jensen, Marion Wiesmann, Emil Kuriakose, Audrey Kauffmann, Astrid Jullion, Ensar Halilovic, Nelson Guerreiro, Jens Würthner, Pascal Furet, Joerg Kallen, Therese-Marie Stachyra, Stephan Ruetz, Marta Cortes-Cros, Swann Gaulis, Eric Y. Durand, Grainne Kerr, Masato Murakami, Vincent Romanet, Dario Sterker, Markus Wartmann, Emilie A. Chapeau, Jeanette Fuchs, Philipp Holzer, Stéphane Ferretti, Sébastien Jeay
Supplementary material and methods include the description for the bioanalytical method for HDM201 detection in plasma and tumor, the human and mouse gene expression analysis in vitro and in vivo, the live-cell quantification of cleaved-caspase activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b82fed93efadb9ad16a5268c6dd4a1d
https://doi.org/10.1158/0008-5472.22420061
https://doi.org/10.1158/0008-5472.22420061
Autor:
Markus Hinder, Inga Ludwig, Christophe Meille, Baldur Magnusson, Michael Looby, Daniel Lorand, Astrid Jullion, Oliver Sander, Steven J. Kovacs, Björn Bornkamp
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1276-1280 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Optimizing new drug therapies remains a challenge for clinical development, despite the use of ever more sophisticated quantitative methodologies. Although conceptually simple, the idea of finding the right treatment at the right dose for the right p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff744331a6a42edb7e7a126badacb955
https://doaj.org/article/15d1549b9b844cf58ce62297612b8cf4
https://doaj.org/article/15d1549b9b844cf58ce62297612b8cf4